Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Mechanistic and Translational Advances Using iPSC-Derived Blood Cells

Version 1 : Received: 26 September 2020 / Approved: 27 September 2020 / Online: 27 September 2020 (08:39:30 CEST)

How to cite: Thom, C.S.; Chou, S.T.; French, D.L. Mechanistic and Translational Advances Using iPSC-Derived Blood Cells. Preprints 2020, 2020090672 (doi: 10.20944/preprints202009.0672.v1). Thom, C.S.; Chou, S.T.; French, D.L. Mechanistic and Translational Advances Using iPSC-Derived Blood Cells. Preprints 2020, 2020090672 (doi: 10.20944/preprints202009.0672.v1).

Abstract

Human induced pluripotent stem cell (iPSC)-based model systems can be used to produce blood cells for the study of both hematologic and non-hematologic disorders. This commentary discusses recent advances that have utilized iPSC-derived red blood cells, megakaryocytes, myeloid cells, and lymphoid cells to model hematopoietic disorders. In addition, we review recent studies that have defined how microglial cells differentiated from iPSC-derived monocytes impact neurodegenerative disease. Related translational insights highlight the utility of iPSC models for studying pathologic anemia, bleeding, thrombosis, autoimmunity, immunodeficiency, blood cancers, and neurodegenerative disease such as Alzheimer’s.

Subject Areas

iPSC; hematopoiesis; developmental biology; anemia; thrombosis; immunodeficiency; cancer

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.